Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03179410 · ClinicalTrials.gov registry record · Phase 2
PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
A Phase 2 study, sponsored by Andrew J. Armstrong, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03179410 is a Phase 2 study that has completed, run by Andrew J. Armstrong, MD. The registered enrollment target is 15 participants.
The verdict
NCT03179410, a Phase 2 study, has completed, sponsored by Andrew J. Armstrong, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of avelumab in patients with metastatic neuroendocrine-like prostate cancer. Eligible men will be started on avelumab every 2 weeks and will stay on therapy until progression or intolerable side effects. The central hypothesis is that PD-L1 inhibition with avelumab will be efficacious based on radiographic responses in a subset of men with metastatic neuroendocrine-like prostate cancer and be reasonably well tolerated, meeting criteria for further study in larger phase 2 and 3 trials based on meeting pre-specified efficacy rates and prolonged PFS in some men.
Interventions
- DRUG Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-02-01 |
| Est. Completion | 2020-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03179410
The ClinicalTrials.gov registry entry for NCT03179410 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew J. Armstrong, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avelumab is the first listed.
NCT03179410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03179410 about?
NCT03179410 is a clinical study titled "PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer". The purpose of this study is to assess the safety and efficacy of avelumab in patients with metastatic neuroendocrine-like prostate cancer. Eligible men will be started on avelumab every 2 weeks and will stay on therapy until progression or intolerable side effects. The central hypothesis is that PD...
What is the current status of trial NCT03179410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2018-02-01. Estimated completion is 2020-12-18.
What interventions are being tested in trial NCT03179410?
The interventions under investigation include: Avelumab (DRUG).
Who is sponsoring clinical trial NCT03179410?
This trial is sponsored by Andrew J. Armstrong, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.